Study of Neuroendocrine Neoplasms and Adrenocortical Carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the natural history of neuroendocrine neoplasms (NENs), including adrenocortical carcinoma (ACC), by collecting tissue samples and clinical data from participants. It focuses on understanding the patterns of disease progression and responses to various therapeutic interventions. Participants will be monitored over time to gather comprehensive data on their conditions, which will aid in improving management strategies for these rare cancers. The study includes individuals with confirmed or suspected NENs and aims to enhance knowledge about these malignancies.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Age \>= 18 years old
* The ability of the participant to understand and the willingness to sign a written consent document.
* Participants with the documentation of:

  * histological or cytological confirmation of NENs or adrenocortical cancer

OR

--biochemical evidence of neuroendocrine tumor (serum/urinary) based on elevated levels of chromogranin A, pancreatic polypeptide, neuron-specific enolase, vasoactive intestinal polypeptide, serotonin (urinary 5-hydroxyindoleacetic acid (5-HIAA)), gastrin, somatostatin, catecholamines, metanephrines, calcitonin, fasting insulin, Cpeptide (proinsulin), glucagon, anterior pituitary hormones

OR

--Suspicion of NEN (from any site/origin) on axial imaging (computed tomography (CT)/ magnetic resonance imaging (MRI) / fluorodeoxyglucose (FDG) positron emission tomography (PET) / 68Ga-Dotatate scan

OR

--a germline genetic variant that predisposes to NETs including ACC.

EXCLUSION CRITERIA:

None

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Jaydira Del Rivero, M.D. — National Cancer Institute (NCI)
• Study coordinator: Anna Liza F Rivero
• Email: anna.rivero@nih.gov
• Phone: (240) 858-7946

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing ADCT-701 for treating neuroendocrine tumors and carcinomas

  This study is testing a new drug called ADCT-701 to see if it can safely help adults with neuroendocrine tumors and certain types of cancer.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06041516

• New DLL3 PET/CT imaging for neuroendocrine tumors compared with standard scans

  A new PET/CT scan using the 68Ga-DLL3 nanobody is being tested to see if it detects metastatic neuroendocrine tumors better than current scans in adults.

  Recruiting at 2 sites Phase 2 Peking University First Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07733024

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• Terbium-161 DOTATATE for metastatic gastro‑enteropancreatic neuroendocrine tumors

  This trial tests terbium-161 DOTATATE, a targeted radioactive drug, in adults with metastatic well-differentiated GEP‑NETs who have progressed after lutetium‑177 therapy.

  Recruiting at 2 sites Phase 2 Tata Memorial Hospital · Mumbai, Maharashtra and 1 other locations · NCT07404176

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• Safety and tolerability of NEUK203-13 CAR-NK cells for DLL3 in advanced neuroendocrine tumors

  This early phase trial tests NEUK203-13, an off-the-shelf CAR-NK cell therapy, in adults with advanced SCLC or other neuroendocrine tumors to see if it is safe and if it shows any anti-tumor activity.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07366658

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.